ITGA2B and ischemic stroke: In a study comprising patients that had suffered an IS or TIA, CD41+/PS−, CD62P+/PS−, and CD142+/PS− were associated with an increased risk of the primary outcome (considered as fatal or non-fatal myocardial infarction and/or fatal or non-fatal recurrent ischaemic stroke), while CD41+/PS+, CD62P+/PS+, and CD142+/PS+ were associated with a decreased risk [36].